Prophylaxis with trimethoprim-sulfamethoxazole caused resistance to develop quickly in isolates of Escherichia coli grown from samples of both faeces and urine.
What does TMP-SMZ stand for?
TMP-SMZ stands for Trimethoprim-Sulfamethoxazole (antibiotic)
This definition appears frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
- Transportation Motor Pool
- Travel Marketing Professional (certification)
- Trimethyl Phosphate
- trimethylol propan
- Trusted Mobile Platform (IBM, Intel, NTT)
- Turbo Molecular Pump
- Theater Master Plan and Construction (Army Corps of Engineers)
- Transmission Maintenance Point International Line (ITU-T)
- Trimethoprim-Sulfamethoxazole (antibiotic)
- Tubular maximum Phosphate Reabsorption per Glomerular Filtration Rate
- Tamil Nadu Medical Practitioners' Association
- Telecommunications Project Management Association
- Temps Moyen Passé en Appel
- Terminal de Muy Pequeña Abertura
- Texas Medical Power of Attorney
- Texas Municipal Police Association
- Texas Municipal Power Agency
- Texture and Modeling, a Procedural Approach (book by D. S. Ebert)
- Total Mycophenolic Acid
Samples in periodicals archive:
Patients are often initially treated with trimethoprim-sulfamethoxazole or a fluoroquinolone for 3 to 4 weeks.
The isolated strain was resistant to [beta]-1actam antimicrobial drugs and trimethoprim-sulfamethoxazole and susceptible to aminoglycosides, tetracyclines, fluoroquinolones, glycopeptides, erythromycin, and rifampin.
Combined surgical and medical treatment was provided; all MRSA isolates showed in vitro susceptibility to clindamycin, trimethoprim-sulfamethoxazole, and rifampin.
The bacteria Methicillin Resistant Staphylococcus (MRSA) was tested for resistance and susceptibility against three antibiotics: clindamycin, erythromycin, and trimethoprim-sulfamethoxazole.
coli infections that were resistant to Bactrim, or trimethoprim-sulfamethoxazole, the antibiotic usually used to treat UTIs.
 Trimethoprim-sulfamethoxazole (TMP-SMZ) is also metabolized by glucuronide conjugation.
Approved February 8, 1995 for the treatment of mild to moderate PCP in patients who are intolerant of Trimethoprim-Sulfamethoxazole (TMP-SMX) Approved January 5, 1999 for the prevention of PCP.